JP2003505420A - 咳を処置するのに使用するノシセプチンレセプタｏｒｌ−１ - Google Patents

咳を処置するのに使用するノシセプチンレセプタｏｒｌ−１

Info

Publication number
JP2003505420A
JP2003505420A JP2001511934A JP2001511934A JP2003505420A JP 2003505420 A JP2003505420 A JP 2003505420A JP 2001511934 A JP2001511934 A JP 2001511934A JP 2001511934 A JP2001511934 A JP 2001511934A JP 2003505420 A JP2003505420 A JP 2003505420A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
hydrogen
phenyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001511934A
Other languages
English (en)
Japanese (ja)
Inventor
ディーン チュールシアン，
ジニー ディー． ホ，
リサ エス． シルバーマン，
ジュリアス ジェイ． マテイシ，
ロビー エル． マックラウド，
ジョン エイ． ヘイ，
リチャード ダブリュー． チャプマン，
アナ バーコビチ，
フランシス エム． カス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2003505420A publication Critical patent/JP2003505420A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
JP2001511934A 1999-07-26 2000-01-26 咳を処置するのに使用するノシセプチンレセプタｏｒｌ−１ Pending JP2003505420A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/359,771 1999-07-26
US09/359,771 US6262066B1 (en) 1998-07-27 1999-07-26 High affinity ligands for nociceptin receptor ORL-1
PCT/US2000/001853 WO2001007050A1 (en) 1999-07-26 2000-01-26 Nociceptin receptor orl-1 agonists for use in treating cough

Publications (1)

Publication Number Publication Date
JP2003505420A true JP2003505420A (ja) 2003-02-12

Family

ID=23415204

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001511934A Pending JP2003505420A (ja) 1999-07-26 2000-01-26 咳を処置するのに使用するノシセプチンレセプタｏｒｌ−１

Country Status (13)

Country Link
US (4) US6262066B1 (US06262066-20010717-C00097.png)
EP (1) EP1200087A1 (US06262066-20010717-C00097.png)
JP (1) JP2003505420A (US06262066-20010717-C00097.png)
CN (1) CN1374865A (US06262066-20010717-C00097.png)
AU (1) AU2629800A (US06262066-20010717-C00097.png)
BR (1) BR0012801A (US06262066-20010717-C00097.png)
CA (1) CA2379398A1 (US06262066-20010717-C00097.png)
HK (1) HK1042236A1 (US06262066-20010717-C00097.png)
HU (1) HUP0203458A3 (US06262066-20010717-C00097.png)
MX (1) MXPA02001033A (US06262066-20010717-C00097.png)
NO (1) NO20020392L (US06262066-20010717-C00097.png)
WO (1) WO2001007050A1 (US06262066-20010717-C00097.png)
ZA (1) ZA200200275B (US06262066-20010717-C00097.png)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037269A1 (ja) * 2003-10-21 2005-04-28 Dainippon Sumitomo Pharma Co., Ltd. 新規ピペリジン誘導体
JP2009513655A (ja) * 2005-10-27 2009-04-02 シェーリング コーポレイション ノシセプチンレセプターｏｒｌ−１のリガンドとしての８−［ビス−（２−クロロ−フェニル）−メチル］−３−フェニル−８−アザ−ビシクロ［３．２．１］オクタン−３−カルボン酸アミド
JP2010516687A (ja) * 2007-01-16 2010-05-20 パーデュー、ファーマ、リミテッド、パートナーシップ 複素環置換ピペリジン化合物とその使用
JP2010523687A (ja) * 2007-04-09 2010-07-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのｏｒｌ−１受容体リガンドとしての１，３，８−三置換−１，３，８−トリアザ−スピロ［４．５］デカン−４−オン誘導体
JP5313865B2 (ja) * 2007-03-01 2013-10-09 田辺三菱製薬株式会社 ベンゾイミダゾール化合物およびその医薬用途
JP2016508142A (ja) * 2012-12-31 2016-03-17 サノビオン・ファーマシューティカルズ・インコーポレイテッドＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 複素環式化合物及びその使用方法
JP2020517745A (ja) * 2017-04-19 2020-06-18 ナショナル ユニヴァーシティ オブ シンガポール Ｂｃｌ−２関連死プロモーター（ｂａｄ）のリン酸化の小分子阻害剤

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067950A1 (en) * 1998-07-27 2004-04-08 Schering-Plough Corporation High affinity ligands for nociceptin receptor ORL-1
WO2001039775A1 (en) * 1999-12-06 2001-06-07 Euro-Celtique, S.A. Benzimidazole compounds having nociceptin receptor affinity
JP3989247B2 (ja) * 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
DE20005049U1 (de) * 2000-03-20 2000-05-18 Dewert Antriebs Systemtech Elektromotorische Antriebseinheit
US6777421B2 (en) 2001-04-10 2004-08-17 Ortho-Mcneil Pharmaceutical, Inc. 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
CA2443672C (en) * 2001-04-12 2011-03-29 Pharmacopeia, Inc. Aryl and biaryl piperidines used as mch antagonists
DE60228072D1 (de) 2001-04-18 2008-09-18 Euro Celtique Sa Benzimidazolon-verbindungen
HUP0402510A3 (en) 2001-04-18 2012-08-28 Euro Celtique Sa Nociceptin analogs and pharmaceutical compositions containing them
AU2002307416B2 (en) 2001-04-18 2005-08-11 Euro-Celtique S.A. Nociceptin analogs
DK1385515T3 (da) 2001-04-18 2008-10-27 Euro Celtique Sa Spiropyrazole forbindelser
ES2316559T3 (es) 2001-04-18 2009-04-16 Euro-Celtique S.A. Compuestos espiroindeno y espiroindano.
WO2002088089A1 (fr) * 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Derives de spiropiperidine, antagonistes du recepteur de nociceptine les contenant en tant qu'ingredient actif et compositions medicinales
WO2002100861A1 (en) * 2001-06-13 2002-12-19 Akzo Nobel N.V. 1-(3-phenyloxypropyl)piperidine derivatives
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
JP2005502619A (ja) * 2001-07-02 2005-01-27 オメロス コーポレイション オピオイドレセプター様レセプター１アゴニストと交替でオピオイドレセプターアゴニストを投与することを含む、痛覚脱失を生成するための方法
FR2827281B1 (fr) * 2001-07-16 2003-12-19 Sanofi Synthelabo Procede pour la preparation de la 4-methylamino-4-phenylpiperidine
FR2827282B1 (fr) 2001-07-16 2004-08-13 Sanofi Synthelabo Procede pour la preparation de 4-amino-4-phenylpiperidines
WO2003030828A2 (en) * 2001-10-09 2003-04-17 Synvax, Inc. Nociceptin-based analgesics
AR037211A1 (es) * 2001-11-07 2004-10-27 Schering Corp Derivados de heteroarilo como ligandos superiores para el receptor de nociceptina orl-1
TW200300757A (en) 2001-11-16 2003-06-16 Schering Corp Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1
US7652039B2 (en) 2002-05-17 2010-01-26 Sequella, Inc. Methods of use and compositions for the diagnosis and treatment of infectious disease
US20040033986A1 (en) 2002-05-17 2004-02-19 Protopopova Marina Nikolaevna Anti tubercular drug: compositions and methods
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
CA2866848C (en) 2002-07-30 2017-01-03 Omeros Corporation Ophthalmologic irrigation solutions and method
WO2004020411A1 (en) * 2002-08-29 2004-03-11 Astrazeneca Ab Naphthamide derivatives and their use
US7081463B2 (en) * 2002-09-09 2006-07-25 Janssen Pharmaceutica N.V. Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders
US7045527B2 (en) * 2002-09-24 2006-05-16 Amgen Inc. Piperidine derivatives
US7696225B2 (en) 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
PE20050250A1 (es) * 2003-07-17 2005-04-08 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
AR045913A1 (es) * 2003-07-17 2005-11-16 Glaxo Group Ltd Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina
SA04250305B1 (ar) * 2003-09-25 2008-06-02 سولفاي فارماسوتيكالز بي . في مشتقات بنزيميدازولون cenzimidazolone وكينازولينون quinazolinone كمساعادات على مستقبلات ORL1 البشرية
CN1893948A (zh) * 2003-10-14 2007-01-10 葛兰素集团有限公司 蕈毒碱性乙酰胆碱受体拮抗剂
WO2005037224A2 (en) * 2003-10-17 2005-04-28 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
TW200524577A (en) * 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
AR046756A1 (es) * 2003-12-12 2005-12-21 Solvay Pharm Gmbh Derivados de hidronopol como agonistas de receptores orl-1 humanos.
US20050228023A1 (en) * 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
EP1725236A4 (en) * 2004-03-11 2009-05-13 Glaxo Group Ltd NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
EP1725564A4 (en) 2004-03-17 2007-09-12 Glaxo Group Ltd ANTAGONISTS OF THE M3 MUSCARIN ACETYL CHOLIN RECEPTOR
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
AR050902A1 (es) * 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
EP1747219A4 (en) * 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
EP1791838A2 (en) * 2004-09-15 2007-06-06 Schering-Plough Ltd. Process for preparing substituted 8-azabicyclo[3.2.1] octan-3-ols
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CN101227903A (zh) * 2005-06-02 2008-07-23 詹森药业有限公司 用作orl-1受体调节剂的新型3-螺环吲哚基衍生物
WO2007011833A2 (en) 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
JP2009503101A (ja) * 2005-08-02 2009-01-29 グラクソ グループ リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2007016639A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US7767691B2 (en) * 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
JP2009507800A (ja) * 2005-09-09 2009-02-26 ユーロ−セルティーク エス．エイ． 縮合およびスピロ環化合物ならびにその使用
WO2007037187A1 (ja) 2005-09-27 2007-04-05 Shionogi & Co., Ltd. Ｐｇｄ２受容体アンタゴニスト活性を有するスルホンアミド誘導体
PE20071159A1 (es) * 2005-10-31 2007-11-30 Schering Corp Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
EP1987009A1 (en) * 2006-01-30 2008-11-05 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
EP1847542A1 (en) * 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
US8796293B2 (en) 2006-04-25 2014-08-05 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
CN101472924A (zh) * 2006-06-20 2009-07-01 惠氏公司 Kv1.5钾通道抑制剂
US20100298342A1 (en) * 2006-09-07 2010-11-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease
AU2007325355A1 (en) * 2006-11-28 2008-06-05 Janssen Pharmaceutica N.V. Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl) -1,3,8-triaza-spiro[4.5]decan-4-one
EP2433935A1 (en) 2007-08-31 2012-03-28 Purdue Pharma LP Substituted-quinoxaline-type-piperidine compounds and the uses thereof
KR101494734B1 (ko) 2007-10-11 2015-02-26 아스트라제네카 아베 단백질 키나제 ｂ 억제제로서 피롤로[2,3-ｄ]피리미딘 유도체
PE20140102A1 (es) 2008-07-21 2014-02-06 Purdue Pharma Lp Compuestos de piperidina puenteada tipo quinoxalina sustituida con actividad sobre el receptor orl-1
GEP20135806B (en) * 2008-11-23 2013-04-10 Pfizer Lactams as beta secretase inhibitors
ITNA20090026A1 (it) * 2009-05-14 2010-11-15 Agostino Bruno D Agonisti del recettore nop e loro usi terapeutici
SG177752A1 (en) 2009-07-27 2012-03-29 Trigemina Inc Methods for treatment of pain
CA2789517A1 (en) 2010-02-12 2011-08-18 The Johns Hopkins University Use of the lactosylceramide synthase isoform b1,4galt-v as a biomarker for cancer
EP2694056B1 (en) 2011-04-01 2019-10-16 AstraZeneca AB Therapeutic treatment
LT2785349T (lt) 2011-11-30 2019-12-10 Astrazeneca Ab Kombinuotas vėžio gydymas
WO2013080036A1 (en) 2011-12-01 2013-06-06 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thereof
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
US20150126516A1 (en) * 2012-05-01 2015-05-07 Sumitomo Chemical Company, Limited Piperidine compound and its use in pest control
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
WO2014102592A2 (en) * 2012-12-27 2014-07-03 Purdue Pharma L.P. Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
US11389473B2 (en) 2015-01-07 2022-07-19 Tonix Pharmaceuticals Holding Corp. Magnesium-containing oxytocin formulations and methods of use
WO2017161017A1 (en) * 2016-03-15 2017-09-21 The Scripps Research Institute Signaling-biased mu opioid receptor agonists
CN117642389A (zh) 2021-07-14 2024-03-01 宜昌人福药业有限责任公司 一种哌啶衍生物及其药物组合物、制备方法和用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633914A (US06262066-20010717-C00097.png) * 1962-06-22
GB1052302A (US06262066-20010717-C00097.png) 1963-04-22
US3318900A (en) 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
US3311264A (en) 1964-12-14 1967-03-28 Arthur W Cayer Measuring and dispensing device
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
US4521537A (en) 1982-08-20 1985-06-04 Hoechst-Roussel Pharmaceuticals Incorporated Spiro[2H-1,4-benzodioxepin-3(5H)4'-piperidine and -3'-pyrrolidine] compounds and their use as antihypertensive agents
DK139684A (da) 1983-04-11 1984-10-12 Janssen Pharmaceutica Nv N-aryl-alpha-amino-carboxamider
CA1261835A (en) 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
JPS61225167A (ja) 1985-03-28 1986-10-06 Yoshitomi Pharmaceut Ind Ltd ベンゾ〔ｇ〕キノリン誘導体
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
HU222344B1 (hu) 1990-10-12 2003-06-28 Merck Frosst Canada & Co. Eljárás telítetlen hidroxi-alkil-kinolinsavak, és ezeket tartalmazó gyógyszerkészítmények előállítására
GB9100505D0 (en) 1991-01-10 1991-02-20 Shell Int Research Piperidine derivatives
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
US5583000A (en) 1991-09-03 1996-12-10 The Regents Of The University Of California Protease-binding compounds and methods of use
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5270324A (en) 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5436255A (en) 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
US5472964A (en) 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
AU691829B2 (en) * 1993-07-16 1998-05-28 Merck & Co., Inc. Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
US5495052A (en) * 1994-09-29 1996-02-27 Arco Chemical Technology, L.P. Process for producing enantiomerically enriched guaifenesin
EP0709375B1 (en) 1994-10-25 2005-05-18 AstraZeneca AB Therapeutic heterocycles
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
DE19519245C2 (de) 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP0742208A1 (en) 1995-05-05 1996-11-13 Grelan Pharmaceutical Co., Ltd. 2-Ureido-benzamide derivatives
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
NZ331160A (en) 1996-02-08 2000-07-28 Merck & Co Inc use of loratadine and a leukotriene antagonist to treat asthma
CA2226058C (en) 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
AU7916798A (en) 1997-05-22 1998-12-11 Boots Company Plc, The Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat
EP0921125B1 (en) 1997-12-05 2002-01-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro[4,5]decan-4-on derivatives
PL342046A1 (en) 1998-01-19 2001-05-21 Pfizer 4-(2-keto-1-benzimidazolinyl)piperidine compounds as agonists of orl1 receptor
US6277991B1 (en) * 1998-05-18 2001-08-21 Novo Nordisk A/S 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
ATE289307T1 (de) * 1998-10-23 2005-03-15 Pfizer 1,3,8-triazaspiro(4,5) decanon verbindungen als orl1-receptor agonisten
AR037211A1 (es) * 2001-11-07 2004-10-27 Schering Corp Derivados de heteroarilo como ligandos superiores para el receptor de nociceptina orl-1

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037269A1 (ja) * 2003-10-21 2005-04-28 Dainippon Sumitomo Pharma Co., Ltd. 新規ピペリジン誘導体
JP2009513655A (ja) * 2005-10-27 2009-04-02 シェーリング コーポレイション ノシセプチンレセプターｏｒｌ−１のリガンドとしての８−［ビス−（２−クロロ−フェニル）−メチル］−３−フェニル−８−アザ−ビシクロ［３．２．１］オクタン−３−カルボン酸アミド
JP2010516687A (ja) * 2007-01-16 2010-05-20 パーデュー、ファーマ、リミテッド、パートナーシップ 複素環置換ピペリジン化合物とその使用
JP5313865B2 (ja) * 2007-03-01 2013-10-09 田辺三菱製薬株式会社 ベンゾイミダゾール化合物およびその医薬用途
JP2010523687A (ja) * 2007-04-09 2010-07-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのｏｒｌ−１受容体リガンドとしての１，３，８−三置換−１，３，８−トリアザ−スピロ［４．５］デカン−４−オン誘導体
JP2016508142A (ja) * 2012-12-31 2016-03-17 サノビオン・ファーマシューティカルズ・インコーポレイテッドＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 複素環式化合物及びその使用方法
JP2020517745A (ja) * 2017-04-19 2020-06-18 ナショナル ユニヴァーシティ オブ シンガポール Ｂｃｌ−２関連死プロモーター（ｂａｄ）のリン酸化の小分子阻害剤
JP7423010B2 (ja) 2017-04-19 2024-01-29 ナショナル ユニヴァーシティ オブ シンガポール Ｂｃｌ－２関連死プロモーター（ｂａｄ）のリン酸化の小分子阻害剤

Also Published As

Publication number Publication date
US6455527B2 (en) 2002-09-24
US6262066B1 (en) 2001-07-17
ZA200200275B (en) 2003-06-25
US20040152707A1 (en) 2004-08-05
BR0012801A (pt) 2002-05-07
US20030073690A1 (en) 2003-04-17
CN1374865A (zh) 2002-10-16
CA2379398A1 (en) 2001-02-01
US7094784B2 (en) 2006-08-22
EP1200087A1 (en) 2002-05-02
HUP0203458A2 (hu) 2003-02-28
HK1042236A1 (zh) 2002-08-09
MXPA02001033A (es) 2002-08-20
NO20020392D0 (no) 2002-01-25
NO20020392L (no) 2002-03-25
US6716846B2 (en) 2004-04-06
HUP0203458A3 (en) 2004-01-28
AU2629800A (en) 2001-02-13
WO2001007050A1 (en) 2001-02-01
US20010011092A1 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
JP2003505420A (ja) 咳を処置するのに使用するノシセプチンレセプタｏｒｌ−１
RU2237060C2 (ru) Соединение, фармацевтическая композиция
JPH06504292A (ja) キヌクリジン誘導体
US20040067950A1 (en) High affinity ligands for nociceptin receptor ORL-1
EP1444200B1 (en) Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1
US7485650B2 (en) High affinity ligands for nociceptin receptor ORL-1
MXPA01001025A (en) High affinity ligands for nociceptin receptor orl-1

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070927